Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anick Bérard, Shannon Strom, Jin-Ping Zhao, Shashi Kori, Detlef Albrecht
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8872f81c01f84aba9c5de34e563332be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8872f81c01f84aba9c5de34e563332be
record_format	dspace
spelling	oai:doaj.org-article:8872f81c01f84aba9c5de34e563332be2021-12-02T17:17:39ZDihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes10.1038/s41598-021-97092-y2045-2322https://doaj.org/article/8872f81c01f84aba9c5de34e563332be2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97092-yhttps://doaj.org/toc/2045-2322Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenital malformations (MCM), and spontaneous abortions (SA) associated with gestational use of DHE or triptans. Three cohort and one nested-case–control analyses were conducted within the Quebec Pregnancy Cohort to assess the risk of prematurity, LBW, MCM, and SA. Exposure was defined dichotomously as use of DHE or triptan during pregnancy. Generalized estimation equations were built to quantify the associations, adjusting for potential confounders. 233,900 eligible pregnancies were included in the analyses on prematurity, LBW, and MCM; 29,104 cases of SA were identified. Seventy-eight subjects (0.03%) were exposed to DHE and 526 (0.22%) to triptans. Adjusting for potential confounders, DHE and triptans were associated with increased risks of prematurity, LBW, MCM, and SA but not all estimates were statistically significant. DHE was associated with the risk of prematurity (aRR: 4.12, 95% CI 1.21–13.99); triptans were associated with the risk of SA (aOR: 1.63, 95% CI 1.34–1.98). After considering maternal migraine, all antimigraine specific medications increased the risk of some adverse pregnancy outcomes, but estimates were unstable.Anick BérardShannon StromJin-Ping ZhaoShashi KoriDetlef AlbrechtNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Anick Bérard Shannon Strom Jin-Ping Zhao Shashi Kori Detlef Albrecht Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
description	Abstract Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenital malformations (MCM), and spontaneous abortions (SA) associated with gestational use of DHE or triptans. Three cohort and one nested-case–control analyses were conducted within the Quebec Pregnancy Cohort to assess the risk of prematurity, LBW, MCM, and SA. Exposure was defined dichotomously as use of DHE or triptan during pregnancy. Generalized estimation equations were built to quantify the associations, adjusting for potential confounders. 233,900 eligible pregnancies were included in the analyses on prematurity, LBW, and MCM; 29,104 cases of SA were identified. Seventy-eight subjects (0.03%) were exposed to DHE and 526 (0.22%) to triptans. Adjusting for potential confounders, DHE and triptans were associated with increased risks of prematurity, LBW, MCM, and SA but not all estimates were statistically significant. DHE was associated with the risk of prematurity (aRR: 4.12, 95% CI 1.21–13.99); triptans were associated with the risk of SA (aOR: 1.63, 95% CI 1.34–1.98). After considering maternal migraine, all antimigraine specific medications increased the risk of some adverse pregnancy outcomes, but estimates were unstable.
format	article
author	Anick Bérard Shannon Strom Jin-Ping Zhao Shashi Kori Detlef Albrecht
author_facet	Anick Bérard Shannon Strom Jin-Ping Zhao Shashi Kori Detlef Albrecht
author_sort	Anick Bérard
title	Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
title_short	Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
title_full	Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
title_fullStr	Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
title_full_unstemmed	Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
title_sort	dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8872f81c01f84aba9c5de34e563332be
work_keys_str_mv	AT anickberard dihydroergotamineandtriptanusetotreatmigraineduringpregnancyandtheriskofadversepregnancyoutcomes AT shannonstrom dihydroergotamineandtriptanusetotreatmigraineduringpregnancyandtheriskofadversepregnancyoutcomes AT jinpingzhao dihydroergotamineandtriptanusetotreatmigraineduringpregnancyandtheriskofadversepregnancyoutcomes AT shashikori dihydroergotamineandtriptanusetotreatmigraineduringpregnancyandtheriskofadversepregnancyoutcomes AT detlefalbrecht dihydroergotamineandtriptanusetotreatmigraineduringpregnancyandtheriskofadversepregnancyoutcomes
_version_	1718381155810541568

Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Ejemplares similares